Practices affEcting macitentan and selexipag patient persistence Rates utilizing pulmonary arterial hypertension clinical Site and patIent perSpecTives (PERSIST): a US qualitative analysis
This real-world study explored factors affecting persistence with macitentan and selexipag treatment from the perspective of 23 healthcare professionals (HCPs) and 134 patients with pulmonary arterial hypertension between 2019 and 2022. Continuous patient/HCP communication and education were key drivers of persistence, as were early discussion and management of side effects.
Authors
- Sean Studer (ORCID: https://orcid.org/0000-0001-9273-392X)
- Martha Kingman (ORCID: https://orcid.org/0000-0002-3560-2066)
- Frances Rogers
- Oksana A. Shlobin (ORCID: https://orcid.org/0000-0003-4131-8499)
- Hafizur Rahman (ORCID: https://orcid.org/0000-0002-2742-049X)
- Colleen McEvoy (ORCID: https://orcid.org/0009-0008-2566-191X)
- Tobore Tobore
- Gabriela Gomez Rendon (ORCID: https://orcid.org/0009-0007-1303-5201)
- Gary Bruce
Institutions
- Johnson & Johnson (United States) (US)
- Washington University in St. Louis (US)
- Inova Fairfax Hospital (US)
- Temple University Hospital (US)
- The University of Texas Southwestern Medical Center (US)
Publication Details
- Journal
- Pulmonary Circulation
- Published
- 2024-10-01
- DOI
- https://doi.org/10.1002/pul2.12441
- Citations
- 5
- Primary Topic
- Pulmonary Hypertension Research and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 2.09
Funders
- Actelion Pharmaceuticals